ImmunoGen : IMGN

IMGN

Stock Data

$31.23

$0.00 (0.00%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

All IMGN Articles

66 Articles

Chris Lange | Sep 9, 2022 at 10:35 AM EDT

Friday’s Big Bounce: Analysts Upgrade or Downgrade Coinbase, 3M, Virgin Galactic and More

Friday's additional top analyst upgrades and downgrades were on CarMax, Coinbase Global, DocuSign, Enphase Energy, ImmunoGen, Navient, 3M, Virgin Galactic…

Chris Lange | Mar 21, 2022 at 11:05 AM EDT

As Markets Flirt With Recovery, More Monday Analyst Upgrades and Downgrades: Check Point Software, Deutsche Bank, Huntsman, ImmunoGen and More

Monday's additional top analyst upgrades and downgrades included Air Products, Blend Labs, Check Point Software, Deutsche Bank, Huntsman and ImmunoGen.

Chris Lange | Dec 1, 2021 at 12:05 PM EST

Wednesday Afternoon’s Analyst Upgrades and Downgrades: Lennar, StoneCo, Vertex Energy and More

Wednesday afternoon's analyst upgrades and downgrades included American Water Works, Corvus Pharmaceuticals, ImmunoGen, Lennar, StoneCo and Vertex Energy.

Chris Lange | Oct 5, 2020 at 12:04 PM EDT

ImmunoGen Sees Solid Win With FDA Update

ImmunoGen shares pushed higher to start out the week when the FDA provided an update for the firm’s treatment of…

Lee Jackson | Oct 2, 2020 at 9:10 AM EDT

Top Analyst Upgrades and Downgrades: American Eagle, Carvana, General Dynamics, Halliburton, Papa Johns, Snowflake, Splunk, Walmart, Workday and More

Friday's top analyst upgrades and downgrades included American Eagle Outfitters, Carvana, General Dynamics, Halliburton, Papa Johns, Snowflake, Splunk, Walmart and…

Chris Lange | Aug 11, 2020 at 9:41 AM EDT

5 Speculative Biotechs With 50% to 300% Implied Upside

24/7 Wall St. has compiled a list of some speculative biotech plays that could see gains of up to 300%…

Chris Lange | Jun 2, 2020 at 8:26 AM EDT

Canaccord Genuity’s Key Takeaways From ASCO

Brokerage firm Canaccord Genuity issued some key takeaways on a few different companies at ASCO. 24/7 Wall St. has also…

Chris Lange | Dec 17, 2019 at 12:15 PM EST

Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study

ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support…

Chris Lange | Sep 30, 2019 at 10:15 AM EDT

Ovarian Cancer Study Suffers Big Setback

ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society…

Jon C. Ogg | Mar 19, 2019 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: Boeing, Booking, Camping World, Domino’s, iRobot, MetLife, Neogen, Southern Copper, Vertex, Worldpay and More

The top analyst upgrades, downgrades and initiations seen on Tuesday included Boeing, Booking, Camping World, Domino's Pizza, iRobot, MetLife, Neogen,…

Jon C. Ogg | Mar 4, 2019 at 8:50 AM EST

Top Analyst Upgrades and Downgrades: Alector, Bed Bath & Beyond, Dillard’s, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx, Zoetis and More

The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro,…

Chris Lange | Mar 1, 2019 at 10:15 AM EST

Is Immunogen Done After This Ovarian Cancer Study?

ImmunoGen shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study.

Lee Jackson | Oct 20, 2018 at 9:20 AM EDT

Jefferies Out With 5 Biotech Stocks Under $10 With Gigantic Upside Potential

Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and…

Jon C. Ogg | Mar 26, 2018 at 11:55 AM EDT

Why ImmunoGen Could See Another 60% of Potential Upside

ImmunoGen shares benefited after the company presented data for its latest assessment of mirvetuximab soravtansine at the Society of Gynecologic Oncology…

Chris Lange | Mar 17, 2018 at 7:55 AM EDT

Even More Biopharma Catalysts Coming Through the End of March

Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates…

1 2 3 … 5

ImmunoGen : IMGN

IMGN

$31.23

All IMGN Articles

Friday’s Big Bounce: Analysts Upgrade or Downgrade Coinbase, 3M, Virgin Galactic and More

As Markets Flirt With Recovery, More Monday Analyst Upgrades and Downgrades: Check Point Software, Deutsche Bank, Huntsman, ImmunoGen and More

Wednesday Afternoon’s Analyst Upgrades and Downgrades: Lennar, StoneCo, Vertex Energy and More

ImmunoGen Sees Solid Win With FDA Update

Top Analyst Upgrades and Downgrades: American Eagle, Carvana, General Dynamics, Halliburton, Papa Johns, Snowflake, Splunk, Walmart, Workday and More

5 Speculative Biotechs With 50% to 300% Implied Upside

Canaccord Genuity’s Key Takeaways From ASCO

Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study

Ovarian Cancer Study Suffers Big Setback

Top Analyst Upgrades and Downgrades: Boeing, Booking, Camping World, Domino’s, iRobot, MetLife, Neogen, Southern Copper, Vertex, Worldpay and More

Top Analyst Upgrades and Downgrades: Alector, Bed Bath & Beyond, Dillard’s, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx, Zoetis and More

Is Immunogen Done After This Ovarian Cancer Study?

Jefferies Out With 5 Biotech Stocks Under $10 With Gigantic Upside Potential

Why ImmunoGen Could See Another 60% of Potential Upside

Even More Biopharma Catalysts Coming Through the End of March

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

ImmunoGen : IMGN

IMGN

$31.23

All IMGN Articles

Friday’s Big Bounce: Analysts Upgrade or Downgrade Coinbase, 3M, Virgin Galactic and More

As Markets Flirt With Recovery, More Monday Analyst Upgrades and Downgrades: Check Point Software, Deutsche Bank, Huntsman, ImmunoGen and More

Wednesday Afternoon’s Analyst Upgrades and Downgrades: Lennar, StoneCo, Vertex Energy and More

ImmunoGen Sees Solid Win With FDA Update

Top Analyst Upgrades and Downgrades: American Eagle, Carvana, General Dynamics, Halliburton, Papa Johns, Snowflake, Splunk, Walmart, Workday and More

5 Speculative Biotechs With 50% to 300% Implied Upside

Canaccord Genuity’s Key Takeaways From ASCO

Why Accelerated Approval Could Be Huge for This Ovarian Cancer Study

Ovarian Cancer Study Suffers Big Setback

Top Analyst Upgrades and Downgrades: Boeing, Booking, Camping World, Domino’s, iRobot, MetLife, Neogen, Southern Copper, Vertex, Worldpay and More

Top Analyst Upgrades and Downgrades: Alector, Bed Bath & Beyond, Dillard’s, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx, Zoetis and More

Is Immunogen Done After This Ovarian Cancer Study?

Jefferies Out With 5 Biotech Stocks Under $10 With Gigantic Upside Potential

Why ImmunoGen Could See Another 60% of Potential Upside

Even More Biopharma Catalysts Coming Through the End of March

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

This High-Yield ETF Combines Bond Investing With Emerging Market Currencies

SoFi Stock Could Jump 26% as Market Overreacts to One Soft Segment

Featured Reads

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

3 Reasons Retirees Should Not Enroll in Medicare Advantage for 2026